# Recombinant Human Bone Morphogenetic Protein-2(rhBMP-2) in Patients With Osteoporosis After Lumbar Fusion

> **NCT05911477** · NA · UNKNOWN · sponsor: **Xijing Hospital** · enrollment: 76 (estimated)

## Conditions studied

- Osteoporosis
- Spinal Fusion

## Interventions

- **DRUG:** RhBMP-2

## Key facts

- **NCT ID:** NCT05911477
- **Lead sponsor:** Xijing Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-07-01
- **Primary completion:** 2023-12-31
- **Final completion:** 2024-06-30
- **Target enrollment:** 76 (ESTIMATED)
- **Last updated:** 2023-06-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05911477

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05911477, "Recombinant Human Bone Morphogenetic Protein-2(rhBMP-2) in Patients With Osteoporosis After Lumbar Fusion". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05911477. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*